A few months ago we investigated the use of unique biomarkers by big biopharma. The use of unique biomarkers served as a measure of innovation for each of the biggest biopharma companies. The most innovative companies are progressing biomarkers to trials more...
This week’s Chart of the Week is an interesting one. We will most likely have a follow up after further analysis of the data from BiomarkerBase. Basically, the chart shows the total commercial usage of a biomarker by company count since the biomarkers first...
In our Charts of the Week over the last several weeks we have been analyzing the use of unique biomarkers by pharmaceutical companies. We are extending that analysis today with a look at the biomarker discovery activity of pharma companies as compared with the number...
Last week our chart of the week was a look at the total number of clinical trials started annually that include biomarkers, with a projection out to 2020. The hockey stick shape of the growth rate was striking, so much so that we decided to follow-up and ask...
In our Chart of the Week post from last week we presented an analysis of the number of unique biomarkers being used by leading drug developers in their clinical trials (unique biomarkers being defined as those that aren’t being used by any other companies). This...
